ST香雪借款重组，公司已连亏5年

Core Viewpoint - ST Xiangxue is facing significant financial difficulties, including ongoing lawsuits and a history of continuous losses over the past five years, prompting the company to seek debt restructuring to alleviate its financial pressures [1][2][3]. Financial Situation - The company has reported a net loss of RMB 6.77 billion, RMB 5.30 billion, RMB 3.89 billion, and RMB 8.59 billion from 2021 to 2024, with an expected loss of RMB 6.35 billion to RMB 9.34 billion in 2025 [2]. - ST Xiangxue's revenue from traditional Chinese medicine accounts for 64.87% of total revenue, while the pharmaceutical manufacturing segment contributes only 22.53%, with a low gross margin of 0.34% [2]. Debt and Legal Issues - The company and its subsidiaries have applied for loans totaling RMB 3.693 billion and RMB 68.1 million, respectively, to support operational needs and reduce debt pressure [1]. - The total amount of guarantees provided by the company and its subsidiaries is approximately RMB 12.18 billion, which exceeds the company's latest audited net assets of RMB 11.54 billion [1]. - As of the announcement date, the company has overdue debts totaling approximately RMB 11.5 billion, which includes amounts related to ongoing lawsuits [1]. Restructuring Efforts - ST Xiangxue is currently in a pre-restructuring phase, which includes a creditor declaration process, with the final guarantee amount to be determined by a temporary administrator [2]. - The pre-restructuring period has been extended multiple times, with the latest extension pushing the deadline to January 11, 2026 [3].